2,566 reports of this reaction
8.6% of all LIFITEGRAST reports
#2 most reported adverse reaction
VISION BLURRED is the #2 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 2,566 FDA adverse event reports linking LIFITEGRAST to VISION BLURRED. This represents approximately 8.6% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience vision blurred should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISION BLURRED is moderately reported among LIFITEGRAST users, representing a notable but not dominant share of adverse events.
In addition to vision blurred, the following adverse reactions have been reported for LIFITEGRAST:
The following drugs have also been linked to vision blurred in FDA adverse event reports:
VISION BLURRED has been reported as an adverse event in 2,566 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISION BLURRED accounts for approximately 8.6% of all adverse event reports for LIFITEGRAST, making it one of the most commonly reported side effect.
If you experience vision blurred while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.